Risk factor
Low default risk
Profitability factor
Very strong margins and returns
About
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or...
Company Valuation
Based on key historical and expected multiples, the stock is overvalued relative to its peers. In particular, the stock is overpriced on P/E, 'expensive' on EV/EBITDA, tr
Target Price
The average target price of VRTX is 531 and suggests 11% upside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recommendation s
Buy
Sell